Chinmay J. Upadhyat becomes Regional Vice President, South Asia for Nikkiso Clean Energy & Industrial Gases Group

TEMECULA, Calif., Feb. 24, 2022 (GLOBE NEWSWIRE) — Nikkiso Cryogenic Industries’ Clean Energy & Industrial Gases Group (“Group”), a part of the Nikkiso Co., Ltd (Japan) group of companies, announces that Chinmay J. Upadhyat has joined the Group as Regional Vice President, South Asia region.

Chinmay will be based in Nikkiso Cosmodyne India Private Ltd, their large manufacturing and competence center in Gujarat India.

This important addition to their management team is the result of growth in the market environment and is in line with the objectives of the Industrial Division of Nikkiso to better serve and support their customers in the Southern Asia Market.

Chinmay started his career in 1995 as a Production Engineer with Anup Engineering and Inductotherm India, then served as key account manager for ten years with Dresser Rand India. Since 2008 he has been Regional then Assistant General Manager for Burckhardt Compression India where he was responsible for sales and business development of new machines for the Indian market.

With his broad experience in the CNG, LNG, H2 and industrial gas markets in India, Chinmay will lead the Nikkiso Clean Energy & Industrial Gases sales and service teams in this important region and embark on a mission to deliver market share growth in a sustainable and profitable way.

“Chinmay will be a perfect addition to our management team with his proficiency in business development, equipment, service, aftermarket sales and market knowledge,” according to Emile Bado, Vice President, Sales & Business Development of the Group.

Chinmay has a Mechanical Engineering degree from Government Polytechnic, Ahmedabad, a Bachelor’s in Technology from JNRVD University, Rajasthan and an MBA from Sikkim Manipal University in Manipal.

ABOUT CRYOGENIC INDUSTRIES
Cryogenic Industries, Inc. (now a member of Nikkiso Co., Ltd.) member companies manufacture engineered cryogenic gas processing equipment and small-scale process plants for the liquefied natural gas (LNG), well services and industrial gas industries. Founded over 50 years ago, Cryogenic Industries is the parent company of ACD, Cosmodyne and Cryoquip and a commonly controlled group of approximately 20 operating entities.

For more information please visit www.cryoind.com and www.nikkiso.com.

MEDIA CONTACT:
Anna Quigley
+1.951.383.3314
aquigley@cryoind.com

Provation appoints Gulf Medical Company as exclusive partner in Saudi Arabia for its market-leading clinical productivity solution

Provation® MD allows clinicians around the world to quickly and accurately document procedures electronically for gastroenterology and respiratory procedures.

Jeddah, Saudi Arabia, and Minneapolis, Minn., USA, Feb. 24, 2022 (GLOBE NEWSWIRE) — Provation, the premier software provider of procedure documentation and clinical decision support solutions, today announced an exclusive partnership with Gulf Medical Company, Ltd., a market leader in medical device and software distribution. The partnership agreement allows Gulf Medical to sell and distribute the global Gold Standard of gastroenterology (GI) and respiratory procedure documentation software, Provation® MD, throughout the Kingdom of Saudi Arabia (KSA).

For more than 25 years, Provation has been a market leader in clinical productivity software. Every day, more than 15,000 physicians and endoscopists in over 5,000 healthcare facilities worldwide use its intuitive workflows, image capture, and deep medical content for gastroenterology and respiratory documentation. Provation MD integrates with existing hospital information systems to replace paper clinical documentation, while improving the consistency, accuracy, and efficiency of procedure notes.

“Gulf Medical looks to its partnership with Provation as a milestone in our diversification into the healthcare IT business stream, which aligns with the Saudi government’s 2030 vision for digitization and Gulf Medical’s vision in bringing the most innovative solutions to the Middle East since 1983,” said Mohamed A. Raouf, Director of Services and New Technologies at Gulf Medical. “As a market leader in its domain, Provation can shift our customers’ experience into a new era of facilitating electronic documentation and reporting and GI workflow management.”

Provation awarded the partnership to Gulf Medical because of its excellent reputation and strong customer relationships with both the private and public hospital sectors throughout the region.

“We are very excited to have Gulf Medical as the exclusive distributor of Provation MD in Saudi Arabia,” said Daniel Hamburger, CEO of Provation. “The Gulf Medical team knows the medical device and software needs of healthcare organizations in their region. This partnership will allow us to further expand Provation’s presence throughout the Kingdom, while empowering more clinicians and endoscopists with the tools they need to deliver quality healthcare for all.”

Gulf Medical plans to rapidly introduce Provation MD to leading healthcare facilities across the Kingdom of Saudi Arabia (KSA).

About Provation

Provation is a leading provider of healthcare software and SaaS solutions for clinical procedure reports, anaesthesia documentation, quality reporting, and more. Provation is best known globally for providing the Gold Standard for gastroenterology (GI) procedure documentation, Provation® MD, and #1 Best in KLAS anaesthesia information management system, Provation® iPro. Our purpose is to empower providers worldwide with the tools they need to deliver quality healthcare for all.

Provation serves more than 5,000 hospitals and health systems, surgery centres, and medical offices, and 700 physician groups worldwide. In 2021, Provation was acquired by Fortive Corporation, a Fortune 1000 company that builds essential technology and accelerates transformation in high-impact fields like workplace safety, engineering, and healthcare. For more information about our solutions, visit provationmedical.com.

About Gulf Medical Company, LTD

Gulf Medical Co. was founded in 1983 to bring the most innovative medical solutions to the Middle East. It is owned by Al-Naghi Group (since 1911) and it serves the medical field in different product lines, bringing many firsts in medical solutions to the region; with a core value that its service does not end at the award of a sale; but only begins at the award and continues for many years to come after, this is side by side to customers and patients. Learn more at www.gulfmedical.com.

Attachment

Tristan Galvan
Provation
612.313.1548
tristan.galvan@provationmedical.com

Eng. Hamza Sheikh
Gulf Medical Company
hamzasheikh@gulfmedical.com

Standard Lithium and Lanxess Finalize Plan for First Commercial Lithium Project in Arkansas

VANCOUVER, British Columbia, Feb. 24, 2022 (GLOBE NEWSWIRE) — Standard Lithium Ltd. (“Standard Lithium” or the “Company”) (TSXV: SLI) (NYSE.A: SLI) (FRA: S5L), an innovative technology and lithium project development company, has reached an agreement (the “Agreement”), dated February 23, 2022, with its strategic partner, LANXESS Corporation (“Lanxess”), that streamlines and expedites the plan for development of the first commercial lithium project in Arkansas, which is to be constructed at an operational Lanxess facility in El Dorado, Arkansas (the “Project”). Under the Agreement, Standard Lithium will control all development of the Project leading up to and including the completion of the Front End Engineering Design (“FEED”) study. Standard Lithium will hold, at a minimum, a 51% majority equity stake in the Project and may retain as much as 100% of the Project. The Company will also retain 100% ownership of its South West Arkansas Project, all its proprietary extraction technologies, relevant intellectual property and know-how.

Robert Mintak, CEO of Standard Lithium commented, “This agreement builds upon the successful working relationship that has been established between the companies. By entering into this Agreement, Standard Lithium takes ownership of the Project and its development timelines with a clear path towards delivering the first new commercial lithium production in the USA in over 50 years.1 We have already begun the process of engaging and integrating the strategic team members to make this project a success.  With the recent investment from our largest shareholder, Koch Strategic Platforms, we are fully funded to complete all planned Project milestones leading to a Definitive Feasibility Study, which is expected to be completed in Q4 2022”.

Key Highlights:

  • Standard Lithium will form an initially wholly-owned company (“Project Company”) that owns 100% of the Project during pre-FEED and FEED engineering studies (see news release dated January 20th, 2022). The FEED engineering will be used to produce a NI43-101 Definitive Feasibility Study (“DFS”) in Q4 2022;
  • Lanxess will, via a series of commercial agreements, provide the brine supply for the Project, the Project site lease, and rights of way, infrastructure, and other services for the Project;
  • Standard Lithium will provide a market fee-based license to the Project Company of its suite of intellectual property;
  • Standard Lithium is able to utilize its intellectual property, extraction technology and know-how at its 100% owned South West Arkansas Project, certain other sites in Arkansas and at all project sites outside of Arkansas, and will maintain control and ownership over the future development of its IP portfolio; and,
  • Lanxess is obliged to support development of the Project and upon completion of a DFS, has the option to acquire an equity interest in the Project Company of up to 49% and not less than 30%, at a price equal to a ratable share of SLL’s aggregate investment in the Project Company.

If Lanxess acquires an ownership interest:

  • The parties will share the costs of financing construction of the Project on a ratable basis; and,
  • Lanxess will have the right to acquire some, or all of the lithium carbonate off-take produced at the commercial plant at market-based terms less a handling fee.

If Lanxess does not acquire an ownership interest:

  • Standard Lithium will own 100% of the Project including customary dividends, distribution, or similar rights;
  • Standard Lithium can elicit bids from other interested parties to buy up to 49% of the Project Company; and,
  • Lanxess will have the right to acquire some, or all of the lithium carbonate off-take produced at the commercial plant at a price of market minus up to 20%, to be agreed by Lanxess and Standard Lithium and taking into consideration several key commercial agreements (including the costs of brine supply and disposal for the Project, the Project site lease cost and rights of way, infrastructure, and other services for the Project).

The parties have also agreed that development of the second and third projects on the Lanxess properties will be on a joint basis and that the parties will perform the same roles using similar contractual structures as the first Project. Lanxess will also have the right to purchase the lithium carbonate off-take from the additional projects upon market-based terms to be agreed by Lanxess and Standard Lithium, taking into consideration other commercial agreements required for their development (e.g. site leases, brine supply/disposal etc.).

Advisors
Stifel Nicolas Canada Inc. acted as financial advisor to Standard Lithium during negotiation of this Agreement.

About Standard Lithium Ltd.
Standard Lithium is an innovative technology and lithium development company. The Company’s flagship project is located in southern Arkansas, where it is engaged in the testing and proving of the commercial viability of lithium extraction from over 150,000 acres of permitted brine operations. The Company operates its first-of-a-kind industrial-scale direct lithium extraction demonstration plant at Lanxess’s south plant facility in southern Arkansas. The demonstration plant utilizes the Company’s proprietary LiSTR technology to selectively extract lithium from Lanxess’s tail brine. The demonstration plant is being used for proof-of-concept and commercial feasibility studies. The scalable, environmentally friendly process eliminates the use of evaporation ponds, reduces processing time from months to hours and greatly increases the effective recovery of lithium. The Company is also pursuing the resource development of over 30,000 acres of separate brine leases located in southwest Arkansas, referred to as the South West Arkansas Lithium Project, and approximately 45,000 acres of mineral leases located in the Mojave Desert in San Bernardino County, California.

Standard Lithium is jointly listed on the TSX Venture Exchange and the NYSE American under the trading symbol “SLI”; and on the Frankfurt Stock Exchange under the symbol “S5L”. Please visit the Company’s website at http://www.standardlithium.com.

On behalf of the Board of Standard Lithium Ltd.
Robert Mintak, CEO & Director

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

This news release may contain certain “Forward-Looking Statements” within the meaning of the United States Private Securities Litigation Reform Act of 1995 and applicable Canadian securities laws. When used in this news release, the words “anticipate”, “believe”, “estimate”, “expect”, “target, “plan”, “forecast”, “may”, “schedule” and other similar words or expressions identify forward-looking statements or information. These forward-looking statements or information may relate to expected development of the Project and future phases, the timeline for completion of the DFS, negotiation of definitive documentation with Lanxess, accuracy of mineral or resource exploration activity, reserves or resources, regulatory or government requirements or approvals, the reliability of third party information, continued access to mineral properties or infrastructure, fluctuations in the market for lithium and its derivatives, changes in exploration costs and government regulation in Canada and the United States, and other factors or information. Such statements represent the Company’s current views with respect to future events and are necessarily based upon a number of assumptions and estimates that, while considered reasonable by the Company, are inherently subject to significant business, economic, competitive, political and social risks, contingencies and uncertainties. Many factors, both known and unknown, could cause results, performance or achievements to be materially different from the results, performance or achievements that are or may be expressed or implied by such forward-looking statements. The Company does not intend, and does not assume any obligation, to update these forward-looking statements or information to reflect changes in assumptions or changes in circumstances or any other events affections such statements and information other than as required by applicable laws, rules and regulations.

1 See https://pubs.usgs.gov/periodicals/mcs2021/mcs2021-lithium.pdf

For further information contact:

LHA Investor Relations
David Barnard
+1 415-433-3777
standardlithium@lhai.com
info@standardlithium.com
Twitter: @standardlithium
LinkedIn: https://www.linkedin.com/company/standard-lithium/

Dante Labs selected as Genetic Tests provider for Abu Dhabi Executive Office Employee’s Wellbeing Week

Dante Labs meets with Abu Dhabi Executive Office

Dante Labs CEO Andrea Riposati and Carlo Logli meet with Dr. Fatima Al Kaabi, Director of Genome Office at Abu Dhabi Executive Office and team.

NEW YORK, Feb. 23, 2022 (GLOBE NEWSWIRE) — Dante Labs, a global leader in genomics and precision medicine, is pleased to announce that the company has been selected as a genetic services provider for Abu Dhabi Executive Office (ADEO) employees for their wellbeing week.

Beginning on February 14, 2022, Dante will be providing whole genome sequencing to ADEO employees as part of the company’s benefit package for all employees.

The testing will be run in the new Dante Dubai laboratory and will provide employees with invaluable insights about their wellness and longevity, including risk of developing certain health conditions, evidence of intolerances to food, and indications for a personalized and balanced diet and fitness training.

“We are very proud to be increasing access to genomic sequencing through this great opportunity to provide our service to ADEO employees. It is through employee testing like this that we are able to deliver invaluable health insights to more people and ultimately better healthcare and longevity,” said Andrea Riposati, CEO of Dante Labs. “The UAE is clearly becoming a global leader in genomics, and we are thrilled to have invested in this amazing country.”

“Not only is this extremely exciting, but we are hopeful that testing programs such as these will pave the way to wider adoption of genomics in other fields such as R&D, training and development programs,” said Prof. Mattia Capulli, Chief Scientific Officer of Dante Labs.

“The Abu Dhabi Executive Office is extremely happy and appreciates Dante Labs for their great service that contributes to our employee’s wellbeing by providing the unique actionable benefit from genomics in both clinical and consumer settings from sports to nutrigenomics,” said Dr. Fatima Al Kaabi, Director of Genome Office, Abu Dhabi Executive Office.

About Dante Labs

Dante Labs is a global genomic data company building and commercializing a new class of transformative health and longevity applications based on whole genome sequencing and AI. Our assets include one of the largest private genome databases with research consent, a proprietary software platform designed to unleash the power of genomic data at scale and proprietary processes which enable an industrial approach to genomic sequencing.

Contact

Laura D’Angelo
VP of Investor Relations
ir@dantelabs.com
+39 0862 191 0671
www.dantelabs.com

A photo accompanying this announcement is available at: https://www.globenewswire.com/NewsRoom/AttachmentNg/95013cb8-6b11-4222-ab49-476331c160f3

PM visits Tomb of Unknown Soldier in Moscow

Prime Minister Imran Khan on Thursday visited the Tomb of the Unknown Soldier to pay tribute to the Soviet soldiers killed during World War II.

The Prime Minister, who is on a two-day official visit to Russia, laid floral wreath at the monument in Moscow.

Members of the Prime Minister’s delegation were also present on the occasion.

Source: Radio Pakistan

Six terrorists killed in North Waziristan operation

Six terrorists were killed by the security forces during an operation in Hamzoni area of North Waziristan district.

According to the ISPR, arms and ammunition was also recovered from the terrorists.

These terrorists were involved in terrorist activities against security forces, target killing and kidnapping for ransom.

Locals of the area have appreciated the operation and expressed their full support to eliminate the menace of terrorism from the area.

Source: Radio Pakistan